Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take ...

This was the stock's second consecutive day of losses.

Biotech company Biogen (NASDAQ:BIIB) in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

Searching For Answers C-Suite Leaders Awards The San Francisco Business Times is now seeking nominations for our annual C-Suite Leaders Awards, which highlights leading local executives and their ...

Biogen appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's ...

Access our full analysis report here, it’s free. Therapeutics company Biogen (NASDAQ:BIIB) jumped 5.1%. Is now the time to buy Biogen? Access our full analysis report here, it’s free.